Stock Report: Pernix Therapeutics Holdings Inc. (PTX) Report Updated: May 20, 2013 | Print This Page

Pernix Therapeutics Holdings, Inc., a pharmaceutical company, focuses on developing, marketing, and selling branded and generic pharmaceutical products for pediatric and adult indications in various therapeutic areas. Its products comprise ALDEX, an antihistamines, decongestants, and cough suppressants for the temporary relief of respiratory allergies, allergic rhinitis, and symptoms of common cold; BROVEX, an antihistamine for the temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose due to hay fever or other respiratory allergies; and CEDAX, a oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogenes. The company also offers NATROBA, a prescription medicine used to treat head lice in adults and children; PEDIATEX, an antihistamine/nasal decongestant liquid for oral administration; and REZYST, a proprietary probiotic blend that promotes the dietary management of patients with the distinctive nutritional requirements associated with the gastro-intestinal flora. In addition, it engages in the development of Theobromine, an alkaloid for persistent cough. The company serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in The Woodlands, Texas.